ESR1 and breast carcinoma: Our study is limited by its small sample size of the ER low-positive and intermediate-positive groups, although this is inherent to the relatively low incidence of these breast cancers in a single centre and the lack of reporting of continuous ER expression in most cancer registries and pathology laboratories.